Supernus Pharmaceuticals Total Non-Operating Income/Expense 2011-2024 | SUPN
Supernus Pharmaceuticals total non-operating income/expense from 2011 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
Supernus Pharmaceuticals Annual Total Non-Operating Income/Expense
(Millions of US $) |
| 2023 |
$8 |
| 2022 |
$15 |
| 2021 |
$-13 |
| 2020 |
$-5 |
| 2019 |
$-1 |
| 2018 |
$-4 |
| 2017 |
$1 |
| 2016 |
$-4 |
| 2015 |
$-6 |
| 2014 |
$-5 |
| 2013 |
$-30 |
| 2012 |
$-4 |
| 2011 |
$-2 |
| 2010 |
$1 |
Supernus Pharmaceuticals Quarterly Total Non-Operating Income/Expense
(Millions of US $) |
| 2024-06-30 |
$4 |
| 2024-03-31 |
$3 |
| 2023-12-31 |
$2 |
| 2023-09-30 |
$2 |
| 2023-06-30 |
$0 |
| 2023-03-31 |
$4 |
| 2022-12-31 |
$1 |
| 2022-09-30 |
$1 |
| 2022-06-30 |
$-0 |
| 2022-03-31 |
$13 |
| 2021-12-31 |
$-4 |
| 2021-09-30 |
$-4 |
| 2021-06-30 |
$-3 |
| 2021-03-31 |
$-2 |
| 2020-12-31 |
$-3 |
| 2020-09-30 |
$-3 |
| 2020-06-30 |
$2 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
$0 |
| 2019-09-30 |
$-0 |
| 2019-06-30 |
$0 |
| 2019-03-31 |
$-1 |
| 2018-12-31 |
$-1 |
| 2018-09-30 |
$-1 |
| 2018-06-30 |
$-2 |
| 2018-03-31 |
$-0 |
| 2017-12-31 |
$1 |
| 2017-09-30 |
$1 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$-1 |
| 2016-12-31 |
$-1 |
| 2016-09-30 |
$-1 |
| 2016-06-30 |
$-1 |
| 2016-03-31 |
$-1 |
| 2015-12-31 |
$-1 |
| 2015-09-30 |
$-1 |
| 2015-06-30 |
$-1 |
| 2015-03-31 |
$-3 |
| 2014-12-31 |
$-1 |
| 2014-09-30 |
$-2 |
| 2014-06-30 |
$-1 |
| 2014-03-31 |
$-2 |
| 2013-12-31 |
$-11 |
| 2013-09-30 |
$-7 |
| 2013-06-30 |
$-12 |
| 2013-03-31 |
$-1 |
| 2012-12-31 |
$-1 |
| 2012-09-30 |
$-1 |
| 2012-06-30 |
$-1 |
| 2012-03-31 |
$-1 |
| 2011-12-31 |
$-0 |
| 2011-09-30 |
$-0 |
| 2011-06-30 |
$-1 |
| 2011-03-31 |
$-1 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.022B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
